AIM Vaccine (HKG:6660) said China's National Medical Products Administration (NMPA) approved clinical trials for its tetanus vaccine, according to a Thursday filing with the Hong Kong bourse.
The company is actively promoting the research and development of diphtheria, tetanus, and acellular pertussis HIB combined vaccine, the Tetravaccine, the filing added.
The company's share prices were up nearly 5% in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。